

Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis

Valtteri Kaasinen,^{1,2} Juho Joutsa,^{1,2} Eero Rissanen,^{1,2} Laura Airas,^{1,2} Merja Soilu-Hänninen,^{1,2} and Tommi Noponen^{3,4}

1. Department of Neurology, University of Turku, Turku, Finland
2. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland
3. Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
4. Department of Medical Physics, Turku University Hospital, Turku, Finland

Key words: multiple sclerosis, dopamine, imaging

Corresponding author:

Dr. Valtteri Kaasinen

Division of Clinical Neurosciences,

Turku University Hospital

POB 52, FIN-20521 Turku, Finland

Tel. 02-3131720

Email: valtteri.kaasinen@tyks.fi

Twitter: @ValKaasinen

Abstract

Dopamine has a modulatory role in a number of autoimmune diseases, but there are no published cases of longitudinal dopaminergic imaging in multiple sclerosis (MS). Here we report a patient with primary progressive multiple sclerosis (PPMS) who was scanned twice with brain dopamine transporter single photon emission computed tomography (SPECT) with an interval of four years. The results showed a loss of tracer binding that corresponded to a 4-7 fold steeper decline than in normal aging. The finding points to a relevant role of nigrostriatal dopaminergic degeneration in the pathological process of PPMS.

1. Introduction

In approximately 15% of patients with multiple sclerosis (MS), the disease course is progressive starting from onset (primary progressive MS, PPMS).¹ The pathogenesis of PPMS is largely unknown but a dynamic interplay between neurodegeneration and neuroinflammation is apparent.¹ Dopamine is a monoamine neurotransmitter that is not classically considered to be particularly important for MS, although there is accumulating evidence of a modulatory role of dopamine in a number of autoimmune diseases.² However, to date, dopamine neurotransmission has not been longitudinally investigated in MS with *in vivo* brain imaging.

In this study, we present a patient who developed an asymmetrical gait disorder and was diagnosed with PPMS. Along with other diagnostic measures, the patient was scanned twice with brain dopamine transporter (DAT) SPECT. The imaging results demonstrated clearly reduced striatal dopaminergic function and a considerably greater annual loss of DAT binding than in normal aging. The case represents the first reported MS patient scanned repeatedly with functional dopaminergic brain imaging.

2. Case report

A 44-year-old man presented with right lower limb muscle stiffness and weakness. Initial examinations for the patient included CNS MRIs and electroneuromyography. The only abnormal finding was a slightly increased signal in cervical spine MRI at the level of the 4th vertebrae, but the lesion was considered unspecific and not clearly abnormal. Symptoms progressed during the next year, and MRI-examinations were repeated with unremarkable findings. CSF at the time of initial examination showed a single oligoclonal fraction not detectable in serum, normal leukocyte count, and slightly elevated protein, albumin and IgG levels; however, IgG index was normal. Due to unclear progressive gait disorder and a family history of Parkinson's disease (PD, mother), a DAT SPECT scan was performed, which revealed a mild loss of dopaminergic function (-1 to -2 SDs from the normal range) (Figure 1D). Brain [¹⁸F]fluorodeoxyglucose PET (Figure 1C) and a whole exome sequencing (Fulgent Genetics, Temple City, CA) were also performed with no pathological findings or mutations. The patient received physiotherapy which was partially beneficial and was treated with levodopa, biperiden, baclofen, selegiline, pramipexole, rotigotine and rasagiline without positive response.

Due to symptom progression and mildly abnormal binding in the first DAT scan, the patient was scanned again four years after the first scan. The second DAT scan showed clear 13-26% reduction in tracer binding which corresponded to a 3.3-6.5% annual decline in all regions (0.9% in normal aging³)(Figure 1B). MRI scanning was repeated and showed typical periventricular MS lesions in the brain as well as multiple chronic lesions in the cervical spine, without striatal abnormalities (Figure 1A). When the earlier MRI was re-evaluated, similar but considerably less numerous and prominent lesions were observed that had not been identified at the time of scanning. The patient received a diagnosis of PPMS according to the McDonald 2017 diagnostic criteria⁴. This was based on symptom

progression, several periventricular, one infratentorial, and several spinal cord lesions consistent with demyelination, together with the exclusion of other causes. The patient is currently receiving treatment with ocrelizumab.

Discussion

PPMS may go unrecognized for some time with a delay in diagnosis.¹ Our case was scanned twice with DAT imaging because the diagnosis remained unclear, partly due to misreading of MRIs. The patient had a gait disorder but no tremor, rigidity or bradykinesia and the whole exome sequencing was normal without any pathological mutations. As a result of repeated SPECT scanning, a progressive degeneration of the nigrostriatal tract was documented that was robustly 4 to 7-fold faster than that in normal aging. Although there are anecdotal reported cases of coexistent MS and PD⁵, there are no previous reported cases of longitudinal functional dopaminergic brain imaging in MS or PPMS. In PD, a condition characterized by a progressive degeneration of the nigrostriatal tract and loss of dopamine, there are relevant autoimmune mechanisms in the pathological process.⁶ It is of interest to note that the distribution of the striatal dopaminergic loss in our PPMS case appears different from PD. While PD is associated with an asymmetric and predominantly posterior putaminal loss of presynaptic dopaminergic function,⁷ PPMS showed more symmetrical, widespread and patchy reduction in DAT binding.

There is some *in vitro* evidence of potential benefit of dopaminergic drugs in MS⁸, that may be mediated not only by the effects on peripheral immune cells but also possibly by direct effects on brain cells of innate immunity.⁹ A dopaminergic drug treatment was tested for our patient, but levodopa or other dopaminergic medications did not alleviate symptoms. It is possible that it is not the loss of dopamine but the prominent axonal damage in PPMS,¹⁰ that is reflected in the accumulating dopaminergic defect. This neurite loss could be relatively resistant to symptomatic dopaminergic drugs.

References

1. Correale J, Gaitán MI, Ysrraelit MC, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. *Brain* 2017; 140: 527-546. DOI: 10.1093/brain/aww258.
2. Pacheco R, Contreras F and Zouali M. The dopaminergic system in autoimmune diseases. *Front Immunol* 2014; 5: 117. 2014/03/21. DOI: 10.3389/fimmu.2014.00117.
3. Karrer TM, Josef AK, Mata R, et al. Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. *Neurobiol Aging* 2017; 57: 36-46. 2017/05/12. DOI: 10.1016/j.neurobiolaging.2017.05.006.
4. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2018; 17: 162-173. 2017/12/21. DOI: 10.1016/S1474-4422(17)30470-2.
5. Valkovic P, Krastev G, Mako M, et al. A unique case of coincidence of early onset Parkinson's disease and multiple sclerosis. *Mov Disord* 2007; 22: 2278-2281. DOI: 10.1002/mds.21642.
6. Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson's disease recognize α -synuclein peptides. *Nature* 2017; 546: 656-661. 2017/06/21. DOI: 10.1038/nature22815.
7. Kaasinen V and Vahlberg T. Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. *Ann Neurol* 2017; 82: 873-882. 2017/12/05. DOI: 10.1002/ana.25103.
8. Marino F and Cosentino M. Multiple sclerosis: Repurposing dopaminergic drugs for MS-- the evidence mounts. *Nat Rev Neurol* 2016; 12: 191-192. 2016/03/29. DOI: 10.1038/nrneurol.2016.33.
9. Pinoli M, Marino F and Cosentino M. Dopaminergic Regulation of Innate Immunity: a Review. *J Neuroimmune Pharmacol* 2017; 12: 602-623. 2017/06/03. DOI: 10.1007/s11481-017-9749-2.
10. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. *J Neurol Neurosurg Psychiatry* 2005; 76: 206-211. DOI: 10.1136/jnnp.2004.043315.

Figure legend

Figure 1. Progressive loss of striatal dopamine function in PPMS without structural or metabolic abnormalities in the striatum.

Brain MRI scanning showed no striatal abnormalities in T2- or T1-weighted sequences (panels A and B; scanning performed after the second DAT SPECT). In addition, [¹⁸F]fluorodeoxyglucose PET was normal (panel C). The first [¹²³I]FP-CIT SPECT scan showed mild patchy losses of DAT binding (panel D). In the second DAT scan four years later (panel E), the dopaminergic defect had progressed by 13-26% (a 4-7 times faster rate than that expected due to normal aging). The defect was not uniform across putaminal subregions and there was also marked decline in the caudate nuclei (panel F, difference in SBR between the scans overlaid on the MNI152 template). Striatal specific binding ratios (SBRs) were calculated relative to the occipital cortex ($SBR = \frac{[striatal\ region - occipital\ cortex]}{occipital\ cortex}$).

